Reuters
Published: 09 Jun 2021 09:29 AM BdST
Updated: 09 Jun 2021 09:29 AM BdST Monira Abbas Bhagasrala, 53, receives a dose of COVISHIELD, a coronavirus disease (COVID-19) vaccine manufactured by Serum Institute of India, at a vaccination centre in Mumbai, India, May 6, 2021. REUTERS
Many more men in India have received COVID-19 vaccines than women, government data showed on Tuesday, highlighting gender disparity in the country s immunisation drive that has also disadvantaged the rural population. );
}
India has partly or fully vaccinated about 101 million men, nearly 17% more than women. Men account for 54% of the total number of people inoculated, according to the data.
Many federally administered regions, the capital Delhi, and big states such as Uttar Pradesh have seen some of the worst inequities. Only Kerala in the south and Chhattisgarh in central India have vaccinated more women than men.
New England Journal of Medicine.
Terlipressin is an investigational product and its safety and effectiveness have not yet been established by the U.S. Food and Drug Administration (FDA) or Health Canada.
As previously announced, the Phase 3 CONFIRM study met its primary endpoint of Verified HRS Reversal, which is defined as renal function improvement, avoidance of dialysis and short-term survival. The main objective of the CONFIRM study was to assess the efficacy and safety of terlipressin, together with albumin, versus placebo in adults in the U.S. and Canada with cirrhosis and HRS-1. The trial met three of the four pre-specified secondary endpoints of the study including HRS reversal,